Biomarkers and prognostic stratification in psoriatic arthritis

L. Bogliolo, G. Crepaldi, R. Caporali

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In rheumatic diseases, biomarkers may serve as surrogate endpoints for diagnosis, prognosis, disease activity, therapeutic response and disease outcome. In recent years a great effort has been made to identify useful tools to establish early diagnosis, prognosis and therapeutic response especially in rheumatoid arthritis (RA). In psoriatic arthritis (PsA) serological biomarkers have been frequently borrowed from RA, but this approach have sometimes lead to inappropriate choices of biomarkers and incorrect conclusions. Furthermore, the heterogeneous spectrum of articular manifestation of PsA and the variable course of the disease can make diagnosis and prognosis difficult. Recently, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) identified two key areas for biomarkers development in psoriasis and PsA: the diagnosis of the articular disease in patients with psoriasis and the evaluation of joint damage in PsA. In this review we revised the currently available and the new potential markers for PsA, such as serum, genetic, cellular and histological biomarkers, clinical and imaging data, with particular attention on the prognostic aspect in order to identify progressive disease suitable for a more aggressive treatment.

Original languageEnglish
Pages (from-to)88-98
Number of pages11
JournalReumatismo
Volume64
Issue number2
Publication statusPublished - 2012

Fingerprint

Psoriatic Arthritis
Biomarkers
Psoriasis
Joints
Rheumatoid Arthritis
Rheumatic Diseases
Early Diagnosis
Therapeutics
Serum
Research

Keywords

  • Biomarkers
  • Joint damage
  • Psoriatic arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Biomarkers and prognostic stratification in psoriatic arthritis. / Bogliolo, L.; Crepaldi, G.; Caporali, R.

In: Reumatismo, Vol. 64, No. 2, 2012, p. 88-98.

Research output: Contribution to journalArticle

@article{604e0ccf03e749a196fd8803b7df42d2,
title = "Biomarkers and prognostic stratification in psoriatic arthritis",
abstract = "In rheumatic diseases, biomarkers may serve as surrogate endpoints for diagnosis, prognosis, disease activity, therapeutic response and disease outcome. In recent years a great effort has been made to identify useful tools to establish early diagnosis, prognosis and therapeutic response especially in rheumatoid arthritis (RA). In psoriatic arthritis (PsA) serological biomarkers have been frequently borrowed from RA, but this approach have sometimes lead to inappropriate choices of biomarkers and incorrect conclusions. Furthermore, the heterogeneous spectrum of articular manifestation of PsA and the variable course of the disease can make diagnosis and prognosis difficult. Recently, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) identified two key areas for biomarkers development in psoriasis and PsA: the diagnosis of the articular disease in patients with psoriasis and the evaluation of joint damage in PsA. In this review we revised the currently available and the new potential markers for PsA, such as serum, genetic, cellular and histological biomarkers, clinical and imaging data, with particular attention on the prognostic aspect in order to identify progressive disease suitable for a more aggressive treatment.",
keywords = "Biomarkers, Joint damage, Psoriatic arthritis",
author = "L. Bogliolo and G. Crepaldi and R. Caporali",
year = "2012",
language = "English",
volume = "64",
pages = "88--98",
journal = "Reumatismo",
issn = "0048-7449",
publisher = "PAGEPRESS PUBL",
number = "2",

}

TY - JOUR

T1 - Biomarkers and prognostic stratification in psoriatic arthritis

AU - Bogliolo, L.

AU - Crepaldi, G.

AU - Caporali, R.

PY - 2012

Y1 - 2012

N2 - In rheumatic diseases, biomarkers may serve as surrogate endpoints for diagnosis, prognosis, disease activity, therapeutic response and disease outcome. In recent years a great effort has been made to identify useful tools to establish early diagnosis, prognosis and therapeutic response especially in rheumatoid arthritis (RA). In psoriatic arthritis (PsA) serological biomarkers have been frequently borrowed from RA, but this approach have sometimes lead to inappropriate choices of biomarkers and incorrect conclusions. Furthermore, the heterogeneous spectrum of articular manifestation of PsA and the variable course of the disease can make diagnosis and prognosis difficult. Recently, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) identified two key areas for biomarkers development in psoriasis and PsA: the diagnosis of the articular disease in patients with psoriasis and the evaluation of joint damage in PsA. In this review we revised the currently available and the new potential markers for PsA, such as serum, genetic, cellular and histological biomarkers, clinical and imaging data, with particular attention on the prognostic aspect in order to identify progressive disease suitable for a more aggressive treatment.

AB - In rheumatic diseases, biomarkers may serve as surrogate endpoints for diagnosis, prognosis, disease activity, therapeutic response and disease outcome. In recent years a great effort has been made to identify useful tools to establish early diagnosis, prognosis and therapeutic response especially in rheumatoid arthritis (RA). In psoriatic arthritis (PsA) serological biomarkers have been frequently borrowed from RA, but this approach have sometimes lead to inappropriate choices of biomarkers and incorrect conclusions. Furthermore, the heterogeneous spectrum of articular manifestation of PsA and the variable course of the disease can make diagnosis and prognosis difficult. Recently, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) identified two key areas for biomarkers development in psoriasis and PsA: the diagnosis of the articular disease in patients with psoriasis and the evaluation of joint damage in PsA. In this review we revised the currently available and the new potential markers for PsA, such as serum, genetic, cellular and histological biomarkers, clinical and imaging data, with particular attention on the prognostic aspect in order to identify progressive disease suitable for a more aggressive treatment.

KW - Biomarkers

KW - Joint damage

KW - Psoriatic arthritis

UR - http://www.scopus.com/inward/record.url?scp=84862488351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862488351&partnerID=8YFLogxK

M3 - Article

C2 - 22690385

AN - SCOPUS:84862488351

VL - 64

SP - 88

EP - 98

JO - Reumatismo

JF - Reumatismo

SN - 0048-7449

IS - 2

ER -